NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- Triple Negative Breast CancerOvarian CarcinomaLeiomyosarcomaAdenocarcinoma - Gastroesophageal Junction (GEJ)Endometrial CancerPeritoneal CarcinomaMesothelioma, MalignantAdenocarcinoma of the StomachMelanoma, MalignantRenal Cell Carcinoma
- Interventions
- Registration Number
- NCT06299163
- Lead Sponsor
- Numab Therapeutics AG
- Brief Summary
This is a first-in-human, open-label, multi-center, Phase 1, dose-escalation study with expansion cohorts to evaluate NM32-2668 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2 dose, define the pharmacokinetics, to explore the pharmacodynamics, and to obtain preliminary evidence of the clinical activity in adult patients with selected advanced solid tumors.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 180
Inclusion Criteria
- Patients with histologically confirmed, advanced-stage protocol-specified solid tumors.
- Confirmed ROR1 tumor expression.
- Patients who have undergone at least one prior systemic therapy and have radiologically or clinically determined progressive disease during or after most recent line of therapy, and for whom no further standard therapy is available, or who are intolerable or have medical contraindications to standard therapy.
Exclusion Criteria
- Prior treatment with any agent targeting ROR1 or prior treatment with a CD3 T-cell engaging therapy.
- Prior treatment with chimeric antigen receptor (CAR) cell therapy within 90 days prior to first dose of NM32-2668.
- Systemic anti-neoplastic therapy within five half-lives or 21 days, whichever is shorter, prior to first dose of NM32-2668.
- Wide-field radiotherapy (> 30% of marrow-bearing bones) within 28 days, or focal radiation for analgesic purpose or for lytic lesions at risk of fracture within 14 days prior to first dose of NM32-2668, or no recovery from side effects of such prior interventions.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description NM32-2668 NM32-2668 -
- Primary Outcome Measures
Name Time Method Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) as assessed by CTCAE v5.0 / ASTCT (for Cytokine Release Syndrome [CRS]) Through 50 days post-final dose administration Incidence of Dose Limiting Toxicities (DLTs) Through 28 days post-infusion Frequency of dose interruptions/reductions Up to 12 treatment cycles or through treatment discontinuation, whichever occurs first Duration of dose interruptions/reductions Up to 12 treatment cycles or through treatment discontinuation, whichever occurs first
- Secondary Outcome Measures
Name Time Method Assessment of the terminal phase (apparent elimination) rate constant (λz) From date of randomization until end of treatment, assessed for up to 336 days (i.e., 12 treatment cycles) or through treatment discontinuation Assessment of the area under the serum concentration-time curve extrapolated from the last quantifiable concentration to infinity (AUC[0-infinity]) From date of randomization until end of treatment, assessed for up to 336 days (i.e., 12 treatment cycles) or through treatment discontinuation Incidence of specific ADAs by category to NM32-2668 From date of randomization until end of treatment, assessed for up to 336 days (i.e., 12 treatment cycles) or through treatment discontinuation Progression-free Survival (PFS) according to RECIST 1.1 From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed through study completion (on average, 1 year after last treatment) Duration of Response (DOR) according to RECIST 1.1 From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed through study completion (on average, 1 year after last treatment) Assessment of the the minimum observed serum concentration (Cmin) From date of randomization until end of treatment, assessed for up to 336 days (i.e., 12 treatment cycles) or through treatment discontinuation Assessment of the elimination half-life (t½) From date of randomization until end of treatment, assessed for up to 336 days (i.e., 12 treatment cycles) or through treatment discontinuation Time from dosing at which maximum observed serum concentration is apparent (Tmax) From date of randomization until end of treatment, assessed for up to 336 days (i.e., 12 treatment cycles) or through treatment discontinuation Disease Control Rate (DCR) according to RECIST 1.1 From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed for up to 30 days following last dose of study treatment Overall Survival (OS) From date of randomization until the date of death from any cause, assessed through study completion (on average, 1 year after last treatment) Assessment of the maximum observed serum concentration (Cmax) From date of randomization until end of treatment, assessed for up to 336 days (i.e., 12 treatment cycles) or through treatment discontinuation Assessment of the volume of distribution (Vd) of NM32-2668 in serum From date of randomization until end of treatment, assessed for up to 336 days (i.e., 12 treatment cycles) or through treatment discontinuation Assessment of accumulation ratios of Cmax (ARcmax) of NM32-2668 in serum From date of randomization until end of treatment, assessed for up to 336 days (i.e., 12 treatment cycles) or through treatment discontinuation Frequency of specific anti-drug antibodies (ADAs) to NM32-2668 From date of randomization until end of treatment, assessed for up to 336 days (i.e., 12 treatment cycles) or through treatment discontinuation Concentration of specific ADAs to NM32-2668 From date of randomization until end of treatment, assessed for up to 336 days (i.e., 12 treatment cycles) or through treatment discontinuation Assessment of the area under serum concentration-time curve over dosing interval (AUCtau) From date of randomization until end of treatment, assessed for up to 336 days (i.e., 12 treatment cycles) or through treatment discontinuation Best Overall Response (BOR) according to RECIST 1.1 From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed for up to 30 days following last dose of study treatment Overall Response Rate (ORR) according to RECIST 1.1 From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed for up to 30 days following last dose of study treatment Assessment of clearance (CL) of NM32-2668 in serum From date of randomization until end of treatment, assessed for up to 336 days (i.e., 12 treatment cycles) or through treatment discontinuation Assessment of accumulation ratios of Cmin (ARcmin) of NM32-2668 in serum From date of randomization until end of treatment, assessed for up to 336 days (i.e., 12 treatment cycles) or through treatment discontinuation Assessment of accumulation ratios of AUC (ARauc) of NM32-2668 in serum From date of randomization until end of treatment, assessed for up to 336 days (i.e., 12 treatment cycles) or through treatment discontinuation Time to Response (TTR) according to RECIST 1.1 From date of randomization until the date of first documented treatment response according to RECIST 1.1
Trial Locations
- Locations (11)
Medical University of South Carolina (MUSC)
🇺🇸Charleston, South Carolina, United States
The University of Chicago Medical Center (UCMC)
🇺🇸Chicago, Illinois, United States
Vanderbilt University Medical Center
🇺🇸Nashville, Tennessee, United States
Froedtert Hospital and the Medical College of Wisconsin
🇺🇸Milwaukee, Wisconsin, United States
University of Alabama at Birmingham
🇺🇸Birmingham, Alabama, United States
USC Norris Comprehensive Cancer Center
🇺🇸Los Angeles, California, United States
Mary Crowley Cancer Research
🇺🇸Dallas, Texas, United States
Duke University
🇺🇸Durham, North Carolina, United States
Lifespan Cancer Institute at Rhode Island Hospital
🇺🇸Providence, Rhode Island, United States
Cleveland Clinic
🇺🇸Cleveland, Ohio, United States
University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center
🇺🇸Pittsburgh, Pennsylvania, United States